



Chelatec


RADIOLIGANDS

- CATALOG -

Table of contents

2-Iodomelatonin [¹²⁵ I]	3
2,5-Dimethoxy-4-iodoamphetamine [¹²⁵ I]	3
AB-MECA [¹²⁵ I]	3
Aminopotentidine [¹²⁵ I]	3
(Sar ¹ , Ile ⁸)-Angiotensin II [¹²⁵ I]	3
(Tyr ⁴)-Bombesin [¹²⁵ I]	3
α-Bungarotoxin [¹²⁵ I]	3
α-CGRP [¹²⁵ I]	3
Cholecystokinin Octapeptide (sulfated) [¹²⁵ I]-SIB	4
α-Dendrotoxin [¹²⁵ I]	4
Echistatin [¹²⁵ I]-SIB	4
Endothelin-1 [¹²⁵ I]	4
Eotaxin [¹²⁵ I]	4
Galanin [¹²⁵ I]	4
Galanin [¹²⁵ I]	4
Ghrelin [¹²⁵ I]	4
IFN-gamma [¹²⁵ I]-SIB	5
Interleukin-8 [¹²⁵ I]	5
Iodo(-)-cyanopindolol [¹²⁵ I]	5
Ioflupane [¹²⁵ I]	5
(Phe ¹³ , Tyr ¹⁹)-MCH [¹²⁵ I]	5
MIBG [¹²⁵ I]	5
MIP-1α [¹²⁵ I]	5
(Nle ⁴ , D-Phe ⁷)-α-MSH [¹²⁵ I]	5
Neurokinin A [¹²⁵ I]	6
Neuromedin U8 [¹²⁵ I]	6
Neurotensin [¹²⁵ I]	6
Peptide YY [¹²⁵ I]	6
Seglitide [¹²⁵ I]	6
(Tyr ¹¹)-Somatostatin-14 [¹²⁵ I]	6
(Leu ⁸ , D-Trp ²² , Tyr ²⁵)-Somatostatin-28 [¹²⁵ I]	6
Substance P [¹²⁵ I]	6
TNF-alpha [¹²⁵ I]	7
Urotensin II [¹²⁵ I]	7
Vasoactive Intestinal Polypeptide [¹²⁵ I]	7
VEGF 165 Protein [¹²⁵ I]-SIB	7
	8
Custom [¹²⁵ I] Radioiodination	8

2-Iodomelatonin [¹²⁵I]




Specific Activity: 2 200 Ci/mmol
81.4 TBq/mmol

Concentration: 0.25 mCi/mL

RCP: ≥ 95%

Reference: RL05 [¹²⁵I]-Iodomelatonin

2,5-Dimethoxy-4-iodoamphetamine [¹²⁵I]




Specific Activity: 2 200 Ci/mmol
81.4 TBq/mmol

Concentration: 0.1 mCi/mL

RCP: ≥ 95%

Reference: RL06 [¹²⁵I]-(+)-DOI

AB-MECA [¹²⁵I]




Specific Activity: 2 200 Ci/mmol
81.4 TBq/mmol

Concentration: 0.1 mCi/mL

RCP: ≥ 95%

Reference: RL24 [¹²⁵I]-AB-MECA

Aminopotentidine [¹²⁵I]



Specific Activity: 2 200 Ci/mmol
81.4 TBq/mmol

Concentration: 0.1 mCi/mL

RCP: ≥ 95%

Reference: RL15 [¹²⁵I]-Aminopotentidine

(Sar¹, Ile⁸)-Angiotensin II [¹²⁵I]

Sequence:
Sar-Arg-Val-Tyr-Ile-His-Pro-Ile-OH

Specific Activity: 2 200 Ci/mmol
81.4 TBq/mmol

Concentration: 0.1 mCi/mL

RCP: ≥ 95%

Reference: RL21 [¹²⁵I]-Sar Ile AT II

(Tyr⁴)-Bombesin [¹²⁵I]

Sequence:
Pyr-Gln-Arg-Tyr-Gly-Asn-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH₂

Specific Activity: 2 200 Ci/mmol
81.4 TBq/mmol

Concentration: 0.1 mCi/mL

RCP: ≥ 95%

Reference: RL23 [¹²⁵I]-Tyr⁸-Bombesin

α-Bungarotoxin [¹²⁵I]

SEQUENCE:
H-Ile-Val-Cys3-His-Thr-Thr-Ala-Thr-Ser-Pro-Ile-Ser-Ala-Val-Thr-Cys16-Pro-Pro-Gly-Glu-Asn-Leu-Cys23-Tyr-Arg-Lys-Met-Trp-Cys29-Asp-Ala-Phe-Cys33-Ser-Ser-Arg-Gly-Lys-Val-Val-Glu-Leu-Gly-Cys44-Ala-Ala-Thr-Cys48-Pro-Ser-Lys-Lys-Pro-Tyr-Glu-Glu-Val-Thr-Cys59-Cy

Specific Activity: 2 200 Ci/mmol
81.4 TBq/mmol

Concentration: 0.1 mCi/mL

RCP: ≥ 85%

Reference: RL17 [¹²⁵I]-α-Bungarotoxin

**α-CGRP [¹²⁵I]
(Human)**

Sequence:
H-Ala-Cys-Asp-Thr-Ala-Thr-Cys-Val-Thr-His-Arg-Leu-Ala-Gly-Leu-Leu-Ser-Arg-Ser-Gly-Gly-Val-Val-Lys-Asn-Asn-Phe-Val-Pro-Thr-Asn-Val-Gly-Ser-Lys-Ala-Phe-NH₂

Specific Activity: 2 200 Ci/mmol
81.4 TBq/mmol

Concentration: 0.05 mCi/mL

RCP: ≥ 90%

Reference: RL12 [¹²⁵I]-α-CGRP

Cholecystokinin Octapeptide (sulfated) [¹²⁵I]-SIB

Sequence:

H-Asp-Tyr(SO₃H)-Met-Gly-Trp-Met-Asp-Phe-NH₂

Specific Activity: 2 200 Ci/mmol
81.4 TBq/mmol

Concentration: 0.1 mCi/mL

RCP: ≥ 95%

Reference: RL04 [¹²⁵I]-CCK8

α-Dendrotoxin [¹²⁵I]

Séquence :

QPRRKL-CILHRN-PGRCYD-KIPAFY-YNQKKK-QCERFD-WSGCCG-NSNRFK-TIEECR-RTCIG

Specific Activity: 2 200 Ci/mmol
81.4 TBq/mmol

Concentration: 0.10 mCi/mL

RCP: ≥ 85%

Reference: RL48 [¹²⁵I]-AlphaDendrotoxin

Echistatin [¹²⁵I]-SIB

Sequence :

H-Glu-Cys-Glu-Ser-Gly-Pro-Cys-Cys-Arg-Asn-Cys-Lys-Phe-Leu-Lys-Glu-Gly-Thr-Ile-Cys-Lys-Arg-Ala-Arg-Gly-Asp-Asp-Met-Asp-Asp-Tyr-Cys-Asn-Gly-Lys-Thr-Cys-Asp-Cys-Pro-Arg-Asn-Pro-His-Lys-Gly-Pro-Ala-Thr-OH (Disulfide bonds between Cys² and Cys¹¹/Cys⁷ and Cys³⁷/Cys⁸ and Cys³⁷/Cys²⁰ and Cys³⁹)

Specific Activity: 80-95 Ci/mmol
2.96-3.5 TBq/mmol

Concentration: 0.1 mCi/mL

RCP: ≥ 95%

Reference: RL40 [¹²⁵I]-Echistatin

Endothelin-1 [¹²⁵I]

(Human, bovine, dog, mouse, porcine, rat)

Sequence:

H-Cys-Ser-Cys-Ser-Ser-Leu-Met-Asp-Lys-Glu-Cys-Val-Tyr-Phe-Cys-His-Leu-Asp-Ile-Ile-Trp-OH

Specific Activity: 2 200 Ci/mmol
81.4 TBq/mmol

Concentration: 0.1 mCi/mL

RCP: ≥ 95%

Reference: RL08 [¹²⁵I]-Endothelin-1

Eotaxin [¹²⁵I]

(Recombinant Human CCL11)

Specific Activity: 2 200 Ci/mmol
81.4 TBq/mmol

Concentration: 0.1 mCi/mL

RCP: ≥ 90%

Reference: RL25 [¹²⁵I]-Eotaxin

Galanin [¹²⁵I]

(Human)

Sequence:

Gly-Trp-Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-Leu-Gly-Pro-His-Ala-Val-Gly-Asn-His-Arg-Ser-Phe-Ser-Asp-Lys-Asn-Gly-Leu-Thr-Ser-OH

Specific Activity: 2 200 Ci/mmol
81.4 TBq/mmol

Concentration: 0.05 mCi/mL

RCP: ≥ 95%

Reference: RL18 [¹²⁵I]-hGalanin

Galanin [¹²⁵I]

(Porcine)

Sequence:

H-Gly-Trp-Thr-Leu-Asn-Ser-Ala-Gly-Tyr-Leu-Leu-Gly-Pro-His-Ala-Ile-Asp-Asn-His-Arg-Ser-Phe-His-Asp-Lys-Tyr-Gly-Leu-Ala-NH₂

Specific Activity: 2 200 Ci/mmol
81.4 TBq/mmol

Concentration: 0.08 mCi/mL

RCP: ≥ 85%

Reference: RL20 [¹²⁵I]-Galanin (porcine)

Ghrelin [¹²⁵I]

(Human)

Sequence:

H-Gly-Ser-Ser(octanoyl)-Phe-Leu-Ser-Pro-Glu-His-Gln-Arg-Val-Gln-Gln-Arg-Lys-Glu-Ser-Lys-Lys-Pro-Pro-Ala-Lys-Leu-Gln-Pro-Arg-OH

Specific Activity: 2 200 Ci/mmol
81.4 TBq/mmol

Concentration: 0.05 mCi/mL

RCP: ≥ 95%

Reference: RL33 [¹²⁵I]-hGhrelin

IFN-gamma [¹²⁵I]-SIB (Recombinant Human)

Specific Activity: 675-845 Ci/mmol
25-31 TBq/mmol

Concentration: 0.25 mCi/mL

RCP: ≥ 95%

Reference: RL41 [¹²⁵I]-IFN-gamma

Interleukin-8 [¹²⁵I] (Recombinant Human CXCL8)

Sequence:
AVLPRSAKEL-RCQCIKTYSK-PFHPKFIKEL-RVIESGPHCA-NTEIIVKLSG-
GRELCLDPKENWVQRVVEKF-LKRAENS


Specific Activity: 2 200 Ci/mmol
81.4 TBq/mmol

Concentration: 0.1mCi/mL

RCP: ≥ 85%

Reference: RL16 [¹²⁵I]-Interleukin-8

Iodo(-)-cyanopindolol [¹²⁵I]




Specific Activity: 2 200 Ci/mmol
81.4 TBq/mmol

Concentration: 0.1 mCi/mL

RCP: ≥ 95%

Reference: RL02 [¹²⁵I]-CYP

Ioflupane [¹²⁵I]



Specific Activity: ≤ 2 200 Ci/mmol
≤ 81.4 TBq/mmol

Concentration: 0.1 mCi/mL

RCP: ≥ 95%

Reference: RL50 [¹²⁵I]-Ioflupane

(Phe¹³,Tyr¹⁹)-MCH [¹²⁵I] (Human, mouse, rat)

Sequence:
H-Asp-Phe-Asp-Met-Leu-Arg-Cys-Met-Leu-Gly-Arg-Val-Phe-Arg-Pro-Cys-
Trp-Gln-Tyr-OH


Specific Activity: 2 200 Ci/mmol
81.4 TBq/mmol

Concentration: 0.05 mCi/mL

RCP: ≥ 95%

Reference: RL28 [¹²⁵I]-MCH

MIBG [¹²⁵I]



Specific Activity: 17.5-2 200 Ci/mmol
0.65-81.4 TBq/mmol

Concentration: 0.2 mCi/mL

RCP: ≥ 95%

Reference: RL45 [¹²⁵I]-MIBG

MIP-1α [¹²⁵I] (Recombinant Human)

Sequence:
ASLAADTPTA-CCFSYTSRQI-PQNFADYFETSSQCSKPGV-IFLTRSRQV-
PSEEWVQ-KYVSDLELSA

Specific Activity: 2 200 Ci/mmol
81.4 TBq/mmol

Concentration: 0.1mCi/mL

RCP: ≥ 85%

Reference: RL32 [¹²⁵I]-MIP-1 alpha/CCL3

(Nle⁴,D-Phe⁷)-α-MSH [¹²⁵I]

Sequence:
Ac-Ser-Tyr-Ser-Nle-Glu-His-D-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH₂

Specific Activity: 2 200 Ci/mmol
81.4 TBq/mmol

Concentration: 0.05 mCi/mL

RCP: ≥ 95%

Reference: RL11 [¹²⁵I]-(NDP)alpha-MSH

Neurokinin A [¹²⁵I]

Sequence:

H-His-Lys-Thr-Asp-Ser-Phe-Val-Gly-Leu-Met-NH₂

Specific Activity: 2 200 Ci/mmol
81.4 TBq/mmol

Concentration: 0.1 mCi/mL

RCP: ≥ 95%

Reference: RL22 [¹²⁵I]-Neurokinin A

Neuromedin U8 [¹²⁵I]

(pig)

Sequence :

H-Tyr-Phe-Leu-Phe-Arg-Pro-Arg-Asn-NH₂

Specific Activity: 2 200 Ci/mmol
81.4 TBq/mmol

Concentration: 0.1 mCi/mL

RCP: ≥ 95%

Reference: RL47 [¹²⁵I]-Neuromedin U8

Neurotensin [¹²⁵I]

Sequence:

pGlu-Leu-Tyr-Glu-Asn-Lys-Pro-Arg-Arg-Pro-Tyr-Ile-Leu

Specific Activity: 2 200 Ci/mmol
81.4 TBq/mmol

Concentration: 0.08 mCi/mL

RCP: ≥ 95%

Reference: RL19 [¹²⁵I]-Neurotensin

Peptide YY [¹²⁵I]

(Human)

Sequence:

H-Tyr-Pro-Ile-Lys-Pro-Glu-Ala-Pro-Gly-Glu-Asp-Ala-Ser-Pro-Glu-Glu-Leu-Asn-Arg-Tyr-Tyr-Ala-Ser-Leu-Arg-His-Tyr-Leu-Asn-Leu-Val-Thr-Arg-Gln-Arg-Tyr-NH₂

Specific Activity: 2 200 Ci/mmol
81.4 TBq/mmol

Concentration: 0.04 mCi/mL

RCP: ≥ 95%

Reference: RL10 [¹²⁵I]-Peptide YY

Seglitide [¹²⁵I]

(MK678)

Sequence:

Cyclo(N-methyl-Ala-tyr-d-trp-lys-val-phe

Specific Activity: 2 200 Ci/mmol
81.4 TBq/mmol

Concentration: 0.1 mCi/mL

RCP: ≥ 95%

Reference: RL37 [¹²⁵I]-MK678

(Tyr¹¹)-Somatostatin-14 [¹²⁵I]

Sequence:

H-Ala-Gly-Cys-Lys-Asn-Phe-Phe-Trp-Lys-Thr-Tyr-Thr-Ser-Cys-OH

Specific Activity: 2 200 Ci/mmol
81.4 TBq/mmol

Concentration: 0.1 mCi/mL

RCP: ≥ 95%

Reference: RL13 [¹²⁵I]- (Tyr¹¹)-Somatostatin-14

(Leu⁸,D-Trp²²,Tyr²⁵)-Somatostatin-28 [¹²⁵I]

Sequence:

H-Ser-Ala-Asn-Ser-Asn-Pro-Ala-Leu-Ala-Pro-Arg-Glu-Arg-Lys-Ala-Gly-Cys-Lys-Asn-Phe-Phe-D-Trp-Lys-Thr-Tyr-Thr-Ser-Cys-OH

Specific Activity: 2 200 Ci/mmol
81.4 TBq/mmol

Concentration: 0.07 mCi/mL

RCP: ≥ 95%

Reference: RL38 [¹²⁵I]-SST28

Substance P [¹²⁵I]

Sequence:

H-Arg-Pro-Lys-Pro-Gln-Gln-Phe-Phe-Gly-Leu-Met-NH₂

Specific Activity: 2 200 Ci/mmol
81.4 TBq/mmol

Concentration: 0.1 mCi/mL

RCP: ≥ 90%

Reference: RL30 [¹²⁵I]-Substance P Lys3

TNF-alpha [¹²⁵I] (Recombinant Human)

Sequence:
 VRSSSRTPSD-KPVAHVVANP-QAEGQLQWLN-RRANALLANG-
 VELRDNQLVV-PSEGLYLIYS-QVLFKGGQCP-STHVLLTHTI-SRIAVSYQTK
 VNLLSAIKSP-CQRETPEGAE-AKPWYEPIYL-GGVFQLEKGD-
 RLSAEINRPD
 -YLDFAESGQV-YFGIIAL

Specific Activity: 500 Ci/mmol
 18.5 TBq/mmol

Concentration: 0.05 mCi/mL

RCP: ≥ 95%

Reference: RL07 [¹²⁵I]-TNF alpha

Urotensin II [¹²⁵I] (Human)

Sequence:
 H-Glu-Thr-Pro-Asp-Cys-Phe-Trp-Lys-Tyr-Cys-Val-OH

Specific Activity: 2 200 Ci/mmol
 81.4 TBq/mmol

Concentration: 0.07 mCi/mL

RCP: ≥ 95%

Reference: RL26 [¹²⁵I]-Urotensin II

Vasoactive Intestinal Polypeptide [¹²⁵I] (human, mouse, rat)

SEQUENCE:
 H-His-Ser-Asp-Ala-Val-Phe-Thr-Asp-Asn-Tyr-Thr-Arg-Leu-Arg-Lys-Gln-
 Met-Ala-Val-Lys-Lys-Tyr-Leu-Asn-Ser-Ile-Leu-Asn-NH₂

Specific Activity: 2 200 Ci/mmol
 81.4 TBq/mmol

Concentration: 0.05 mCi/mL

RCP: ≥ 95%

Reference: RL03 [¹²⁵I]-VIP

VEGF 165 Protein [¹²⁵I]-SIB (Recombinant Human)

Specific Activity: 1000-2500 Ci/mmol
 37-92.6 TBq/mmol

Concentration: 0.1 mCi/mL

RCP: ≥ 85%

Reference: RL44 [¹²⁵I]-rhVEGF

Custom [¹²⁵I] Radioiodination

Radioiodination of proteins and peptides may be performed by different methods, namely by targeting an iodine-accepting group on the protein or by the conjugation of a small radioiodinated molecule on terminal amino groups.

Direct radioiodination

Iodogen[®], **Chloramine-T** or **Lactoperoxidase** lead to the *in situ* preparation of an electrophilic radioiodine species, which reacts with tyrosine groups.

Indirect radioiodination (conjugation method)

This labelling method provides an alternative way to introduce radioiodine into proteins using a prosthetic group labelled at high specific.

- Bolton Hunter's method is the most well known procedure.
- The *N-succinimidyl-3-trimethylstannylbenzoate* is also used, as it is more stable to *in vivo* dehalogenation.

Our experienced radiochemists will provide a tailored and collaborative service, adapted to your specific needs. Our products are delivered with a comprehensive certificate of analysis comprising:

- Radiochemical purity
- Specific activity
- Total amount of activity
- Radio HPLC

RELIABLE

PARTNER
FOR RELIABLE
MOLECULES

Chelatec SAS

1 rue Aronnax, 44800 Saint-Herblain, France

TEL: 33 (0)2 51 86 19 59

FAX: 33 (0)2 51 86 15 65

www.chelatec.com

contact@chelatec.com